<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530841</url>
  </required_header>
  <id_info>
    <org_study_id>2010-A01306-33</org_study_id>
    <nct_id>NCT01530841</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy</brief_title>
  <official_title>Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Investigation Clinique et Technologique 805</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adep Assistance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d'Investigation Clinique et Technologique 805</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myotonic dystrophy type 1 is a myopathy with complex respiratory pattern and at risk to
      develop respiratory failure. Classical mode of ventilation are sometimes not tolerated or
      ineffective in this population. New modes of nocturnal ventilation by combining both
      volumetric and barometric advantages. The aim of this study is to compare effect of AVAPS
      mode to bilevel pressure support.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification of study

      Respiratory abnormalities are complex in Myotonic dystrophy type 1. Some patients presented
      with isolated alveolar hypoventilation and breathe rhythm irregularity. Nocturnal ventilation
      is usually proposed but usual modes of ventilation can't provide enough respiratory
      assistance for patients especially during REM sleep or too much respiratory assistance
      increasing the risk of asynchrony. The goal of this study is to evaluate the effect of the
      mode AVAPS (a mode permitting a pressure support with guaranteed volume and offering
      advantage of volume and pressure support with Bipap A30 Phillips Respironics) compared to
      bilevel pressure support.

      Main Objective To evaluate efficacy of AVAPS Mode at day 7 on arterial PCO2 under ventilation
      after launching ventilation.

      Secondary Objectives To evaluate efficacy of AVAPS Mode at day 90 on daytime arterial PCO2
      after launching ventilation.

      To evaluate compliance to ventilation at day 7 and 90. To evaluate clinical efficacy on
      respiratory symptoms, dyspnea and sleepiness at day 1 and 90.

      To evaluate quality of life at day 1 and 90. To evaluate effect of AVAPS on polysomnography,
      nocturnal SaO2, nocturnal PtCO2.

      To evaluate Multiple sleep latency and Maintenance of wakefulness tests at day 90.

      To evaluate effect of AVAPS on respiratory parameters VC and mouth maximal pressures.

      Type of study: Prospective, monocentre, randomized, controlled single blind study on 2
      parallel group.

      Number of subjects: 32 patients recruited in home ventilation unit of Raymond Poincaré
      hospital.

      Selection criteria : Patients with Myotonic dystrophy presenting at least one clinical signs
      : effort or rest dyspnea, orthopnea, sleepiness, morning headache or VC&lt;50% or Pi max&lt; 60 cm
      H2O or time of SaO2&lt;90% more than 5 minutes and Hypercapnia &gt; 6.0 kPa.

      Study process Preceding screening period within the 3 months before inclusion. Day 1 to day 3
      baseline evaluation. Day 3 Inclusion and Randomisation Day 3 to 8 Launch of ventilation Day 8
      Home discharge Day 90 Evaluation of efficacy (secondary objectives) and observance.

      Duration Participation of a patient 3 months. Period of inclusion 24 months. Total duration
      of study 30 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial PCO2 under ventilation</measure>
    <time_frame>7 days</time_frame>
    <description>To evaluate efficacy of AVAPS Mode versus bilevel pressure mode at day 7 on arterial PCO2 under ventilation after launching ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>daytime arterial PCO2 after launching ventilation.</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate efficacy of AVAPS Mode at day 90 on daytime arterial PCO2 after launching ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to ventilation</measure>
    <time_frame>7 and 90 days</time_frame>
    <description>To evaluate compliance (h/24h) to ventilation at days 7 and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate clinical efficacy on respiratory symptoms, dyspnea and sleepiness at day 1 and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep studies</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate effect of AVAPS on polysomnography, nocturnal SaO2, nocturnal PtCO2 at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OBJECTIVE SLEEPINESS</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate Multiple sleep latency and Maintenance of wakefulness tests at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate effect of AVAPS on respiratory parameters VC and mouth maximal pressures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Myopathy</condition>
  <arm_group>
    <arm_group_label>AVAPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilevel pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nocturnal ventilation</intervention_name>
    <description>Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.</description>
    <arm_group_label>AVAPS</arm_group_label>
    <arm_group_label>Bilevel pressure</arm_group_label>
    <other_name>BIPAP A30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged &gt; 18 years

          -  Written consent

          -  DM1 myotonic dystrophy

          -  One clinical signs dyspnea rest/effort, orthopnea, daytime sleepiness (Epworth&gt; 10),
             morning headache.

        Or restrictive syndrome: VC&lt; 50 % or Pi max &lt;60 cm H2O Or time of nocturnal saturation &lt; 90
        %, &gt; 5 minutes. AND Hypercapnia &gt; 6.0 kPa Pregnancy test negative or use of contraception
        for women in age of procreation

        Exclusion Criteria:

          -  Patient using previously home ventilation within the 6 months before entering the
             study

          -  Patient denying home ventilation

          -  Refusal to sign consent

          -  impossibility to be followed during 3 months

          -  Impossibility to apply ventilation at home

          -  No social/health coverage

          -  Patient under tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David ORLIKOWSKI, Md-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raymond Poincare Hospital - Garches - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Home ventilation Unit , Raymond Poincaré hospital</name>
      <address>
        <city>Garches</city>
        <state>Paris Area</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre d'Investigation Clinique et Technologique 805</investigator_affiliation>
    <investigator_full_name>david orlikowski</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Myotonic dystrophy type 1</keyword>
  <keyword>Home ventilation</keyword>
  <keyword>Respiratory insufficiency</keyword>
  <keyword>Neuromuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

